Replication of the Heads Up Atopic Dermatitis Trial With Registry Data
ConditionAtopic Dermatitis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorTechnische Universität Dresden
About this trial
The goal is the replication of the primary outcome (EASI 75 at week 16) of the Heads Up trial (Blauvelt, A, Teixeira, H, Simpson, E et al (2021) doi:10.1001/jamadermatol.2021.3023) and the evaluation of the patient reported outcomes (POEM, DLQI and RECAP) in a head-to-head comparison of upadacitinib versus dupilumab treatment in moderate-to-severe atopic dermatitis (AD).
Eligibility criteria
Qualifiers
Chronic AD with onset of symptoms at least 3 years prior to baseline
Meets UK working party criteria
EASI score ≥ 16
≥ 10% body surface area (BSA) of AD involvement at baseline ("therapy start") visit
Disqualifiers
contraindications according to upadacitinib or dupilumab labeling
Trial design
Treatments tested in this trial
- Upadacitinib
- Dupilumab
Treatment groups
240 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov